Frequency of autoimmune diseases secondary to biologic drugs used in rheumatic disorders (bio-DMARDS) is increasing. Reports of renal diseases is also increasing. The literature reports small series and many case reports of association between the use of a biologic drug and glomerular, vascular or interstitial nephropathies elapsing several months to more than 3 years from the beginning of treatment. Some of the reported glomerular diseases are already known to be possibly associated to the rheumatic disease. Prevention consists in careful clinical, immunologic and renal evaluation before giving bioDMARDS and in careful monitoring. These nephropathies and autoimmune diseases may go into remission just by drug discontinuation, which is mandatory in case of renal, nervous and pulmonary involvement. Corticosteroids or immunsuppressive drugs may be necessary.
[Biologic drug-induced nephropathies]
ROCCATELLO, Dario
Last
2015-01-01
Abstract
Frequency of autoimmune diseases secondary to biologic drugs used in rheumatic disorders (bio-DMARDS) is increasing. Reports of renal diseases is also increasing. The literature reports small series and many case reports of association between the use of a biologic drug and glomerular, vascular or interstitial nephropathies elapsing several months to more than 3 years from the beginning of treatment. Some of the reported glomerular diseases are already known to be possibly associated to the rheumatic disease. Prevention consists in careful clinical, immunologic and renal evaluation before giving bioDMARDS and in careful monitoring. These nephropathies and autoimmune diseases may go into remission just by drug discontinuation, which is mandatory in case of renal, nervous and pulmonary involvement. Corticosteroids or immunsuppressive drugs may be necessary.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
